Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of dasiglucagon vs placebo and GlucaGen HypoKit for severe hypoglycemia rescue in children with type 1 diabetes mellitus
2018-000892-33Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dasiglucagon in diabetes mellitus type 1 (T1D) and hypoglycaemia (3 arms), sponsored by Zealand Pharma. Primary endpoint: Time to plasma glucose recovery. Started Jul 2018; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)hypoglycaemia
Beyond the preview
Go deeper on 2018-000892-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000892-33.